Xufen Yu

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 17

Top Topics

Acute Myeloid Leukemia

Multiple Myeloma

Transcription Factor

Top Venues

Journal of medicinal chemistry

Journal of the American Chemical Society

This page only lists publications with an associated author ORCID identifier.

Publications

Jing Liu, Xiaoping Hu, Kaixiu Luo, Yan Xiong, Li Chen, Zhen Wang, Hiroyuki Inuzuka, Chao Qian, Xufen Yu, Ling Xie, Adil Muneer, Dingpeng Zhang, Joao A Paulo, Xian Chen, Jian Jin, Wenyi Wei
USP7-Based Deubiquitinase-Targeting Chimeras Stabilize AMPK. Journal of the American Chemical Society (2024)
Joshua Corbin, Xufen Yu, Jian Jin, Ling Cai, Gang Greg Wang
EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth. Oncogene (2024)
Joshua Corbin, Xufen Yu, Jian Jin, Ling Cai, Gang Greg Wang
EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth. Oncogene 43 (36) (2024)
Xufen Yu, Jun Wang, Weida Gong, Anqi Ma, Yudao Shen, Chengwei Zhang, Xijuan Liu, Ling Cai, Jing Liu, Gang Greg Wang, Jian Jin
Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. Oncogene (2023)
Xufen Yu, Jun Wang, Weida Gong, Anqi Ma, Yudao Shen, Chengwei Zhang, Xijuan Liu, Ling Cai, Jing Liu, Gang Greg Wang, Jian Jin
Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. Oncogene (2023)
Xufen Yu, Jun Wang, Weida Gong, Anqi Ma, Yudao Shen, Chengwei Zhang, Xijuan Liu, Ling Cai, Jing Liu, Gang Greg Wang, Jian Jin
Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. Oncogene 42 (13) (2023)
Xufen Yu, Dong-Xu Li, Jithesh Kottur, Huen Suk Kim, Laura E Herring, Yao Yu, Ling Xie, Xiaoping Hu, Xian Chen, Ling Cai, Jing Liu, Aneel K Aggarwal, Gang Greg Wang, Jian Jin
Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer. Journal of medicinal chemistry (2023)
Xufen Yu, Jun Wang, Weida Gong, Anqi Ma, Yudao Shen, Chengwei Zhang, Xijuan Liu, Ling Cai, Jing Liu, Gang Greg Wang, Jian Jin
Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. Oncogene (2023)
Alex Rialdi, Mary Duffy, Alex P Scopton, Frank Fonseca, Julia Nanyi Zhao, Megan Schwarz, Pedro Molina-Sanchez, Slim Mzoughi, Elisa Arceci, Jordi Abril-Fornaguera, Austin Meadows, Marina Ruiz de Galarreta, Denis Torre, Kyna Reyes, Yan Ting Lim, Felix Rosemann, Zaigham M Khan, Kevin Mohammed, Xuedi Wang, Xufen Yu, Manikandan Lakshmanan, Ravisankar Rajarethinam, Soo Yong Tan, Jian Jin, Augusto Villanueva, Eleftherios Michailidis, Ype P De Jong, Charles M Rice, Ivan Marazzi, Dan Hasson, Josep M Llovet, Radoslaw Mikolaj Sobota, Amaia Lujambio, Ernesto Guccione, Arvin C Dar
WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma. Nature cancer (2023)
Xufen Yu, Jun Wang, Weida Gong, Anqi Ma, Yudao Shen, Chengwei Zhang, Xijuan Liu, Ling Cai, Jing Liu, Gang Greg Wang, Jian Jin
Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. Oncogene (2023)
Xufen Yu, Jia Xu, Kaitlyn M Cahuzac, Ling Xie, Yudao Shen, Xian Chen, Jing Liu, Ramon E Parsons, Jian Jin
Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells. Journal of medicinal chemistry 65 (20) (2022)
Brandon Dale, Chris Anderson, Kwang-Su Park, Husnu Ümit Kaniskan, Anqi Ma, Yudao Shen, Chengwei Zhang, Ling Xie, Xian Chen, Xufen Yu, Jian Jin
Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2. ACS pharmacology & translational science 5 (7) (2022)
Xufen Yu, Meng Cheng, Kaylene Lu, Yudao Shen, Yue Zhong, Jing Liu, Yue Xiong, Jian Jin
Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras. Journal of medicinal chemistry 65 (12) (2022)
Jing Liu, Xufen Yu, He Chen, Husnu Ümit Kaniskan, Ling Xie, Xian Chen, Jian Jin, Wenyi Wei
TF-DUBTACs Stabilize Tumor Suppressor Transcription Factors. Journal of the American Chemical Society 144 (28) (2022)
Dongxu Li, Xufen Yu, Jithesh Kottur, Weida Gong, Zhao Zhang, Aaron J Storey, Yi-Hsuan Tsai, Hidetaka Uryu, Yudao Shen, Stephanie D Byrum, Rick D Edmondson, Samuel G Mackintosh, Ling Cai, Zhijie Liu, Aneel K Aggarwal, Alan J Tackett, Jing Liu, Jian Jin, Gang Greg Wang
Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic. Oncogene 41 (24) (2022)
Wesley L Cai, Jocelyn Fang-Yi Chen, Huacui Chen, Emily Wingrove, Sarah J Kurley, Lok Hei Chan, Meiling Zhang, Anna Arnal-Estape, Minghui Zhao, Amer Balabaki, Wenxue Li, Xufen Yu, Ethan D Krop, Yali Dou, Yansheng Liu, Jian Jin, Thomas F Westbrook, Don X Nguyen, Qin Yan
Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation. eLife 11 (2022)
Xufen Yu, Dongxu Li, Jithesh Kottur, Yudao Shen, Huen Suk Kim, Kwang-Su Park, Yi-Hsuan Tsai, Weida Gong, Jun Wang, Kyogo Suzuki, Joel S Parker, Laura E Herring, Husnu Ümit Kaniskan, Ling Cai, Rinku Jain, Jing Liu, Aneel K Aggarwal, Gang Greg Wang, Jian Jin
A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models. Science translational medicine 13 (613) (2021)